Anxiolytic effects in the plus-maze of 5-HT1A-receptor ligands in dorsal raphé and ventral hippocampus

Pharmacology Biochemistry and Behavior

Volumn 54, Issue 1, 1996, Pages 123-128

  File, Sandra E ^a   Gonzalez, Luis E ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

5 HT1A receptors; Anxiety; Dorsal raph ; Hyperactivity; Plus maze; Ventral hippocampus; Receptors

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; ANXIOLYTIC AGENT; BETA ADRENERGIC RECEPTOR; SEROTONIN 1A AGONIST; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; TERTATOLOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; CONFERENCE PAPER; CONTROLLED STUDY; DORSAL RAPHE NUCLEUS; DRUG ANTAGONISM; EXPERIENCE; HIPPOCAMPUS; HISTOLOGY; HYPERACTIVITY; INTRACEREBRAL DRUG ADMINISTRATION; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; HIPPOCAMPUS; LIGANDS; MALE; PROPANOLAMINES; RAPHE NUCLEI; RATS; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; STEREOTAXIC TECHNIQUES; THIOPHENES;

EID: 0029975099     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/0091-3057(95)02108-6     Document Type: Article

References (28)

1. Boudier, H. S.; Abbott, A. Novel antihypertensive drug reveals unexpected complexities in β-adrenoceptor pharmacology. Trends Pharmacol. Sci. 10:469-71; 1989.
2. Carli, M.; Prontera, C.; Samanin, R. Evidence that central 5-hydroxytryptaminergic neurones are involved in the anxiolytic activity of buspirone. Br. J. Pharmacol. 96:829-836; 1989.
3. 1A receptor agonist. Psychopharmacology 94:84-91; 1988.
4. 1A receptors. Chichester: Ellis Horwood; 1987:261-278.
5. File, S. E. One-trial tolerance to the anxiolytic effects of chlordiazepoxide in the plus-maze. Psychopharmacology 100:281-288; 1990.
6. File, S. E. The biological basis of anxiety. In: Meltzer, Y.; Nerozzi, D., eds. Current practices and future developments in the pharmacology of mental disorders. Amsterdam: Excerpta Medica; 1991:159-166.
7. File, S. E. The interplay of learning and anxiety in the elevated plus-maze. Behav. Brain Res. 58:199-202; 1993.
8. File, S. E. Animal models of different anxiety states. In: Biggio, G.; Sanna, E.; Cost, E., eds. GABAA receptors and anxiety. New York: Raven Press; 1995:93-113.
9. File, S. E.; Zangrossi, H.; Viana, M.; Graeff, F. Trial 2 in the elevated plus-maze: A different form of fear? Psychopharmacology 111:491-494; 1993.
10. Griebel, G. 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders - more than 30 years research. Pharmacol. Ther. 65:319-395; 1995.
11. Handley, S. L.; McBlane, J. W.; Critchley, M. A. E.; Njung'e, K. Serotonin mechanisms in animal models of anxiety: Environmental, emotional and cognitive factors. Behav. Brain Res. 58: 203-210; 1993.
12. 1-like and GABA receptors in the dorsal raphé nucleus of the rat. Neuropharmacology 27:993-1001; 1988.
13. Hogg, S.; Andrews, N.; File, S. E. Contrasting behavioural effects of 8-OH-DPAT in the dorsal raphé nucleus and ventral hippocampus. Neuropharmacology 33:343-348; 1994.
14. Hutson, P. H.; Sarna, G. S.; O'Connell, M. T.; Curzon, G. Hippocampal 5-HT synthesis and release in vivo is decreased by infusion of 8-OH-DPAT into the nucleus raphé dorsalis. Neurosci. Lett. 100:276-280; 1989.
15. Johnston, A. L.; File, S. E. Can animal tests of anxiety detect panic-promoting agents? Hum. Psychopharmacol. 3:149-152; 1988.
16. 1A receptors in the rat brain. Naunyn-Schmied. Arch. Pharmacol. 347:453-463; 1993.
17. New, J. S. The discovery and development of buspirone: A new approach to the treatment of anxiety. Med. Res. Rev. 10:283-326; 1990.
18. Paxinos, G.; Watson, C. The rat brain in stereotaxic coordinates. London: Academic Press; 1986.
19. Fellow, S.; Chopin, P.; File, S. E.; Briley, M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods 14:149-167; 1985.
20. 1A compounds 8-hydroxy-2-(di-n-propylamino)tetralin and ipsapirone in the social interaction paradigm: Evidence of a presynaptic action. Brain Res. Bull. 37:169-175; 1995.
21. 1A) receptor antagonist in rat brain. J. Pharmacol. Exp. Ther. 265:739-744; 1993.
22. 1A-receptor antagonist, in murine elevated plus-maze test. Eur. J. Pharmacol. 261:321-325; 1994.
23. Rodgers, R. J.; Cole, J. C. The elevated plus-maze: Pharmacology, methodology and ethology. In: Cooper, S. J.; Hendrie, C. A., eds. Ethology and psychopharmacology. Chichester: Wiley; 1994:9-44.
24. 1A-receptor agonists 8-OH-DPAT, ipsapirone and buspirone in the rat. Eur. J. Pharmacol. 249:341-351; 1993.
25. Sharp, T.; Bramwell, S. R.; Clark, D.; Grahame-Smith, D. G. In vivo measurement of extracellular 5-hydroxytryptamine in hippocampus of the anaesthetized rat using microdialysis: Changes in relation to 5-hydroxytryptaminergic neuronal activity. J. Neurochem. 53:234-240; 1990.
26. 1B agonists. Synapse 1:3-9; 1987.
27. Tunnicliff, G. Molecular basis of buspirone's anxiolytic action. Pharmacol. Toxicol. 69:149-146; 1991.
28. Wright, I. K.; Upton, N.; Marsden, C. A. Effect of established and putative anxiolytics on extracellular 5-HT and 5-HIAA in ventral hippocampus of rats during behaviour on the elevated X-maze. Psychopharmacology 109:338-346; 1992.